CA2348779A1 - Detecteurs moleculaires polynucleotidiques a domaines multiples - Google Patents

Detecteurs moleculaires polynucleotidiques a domaines multiples Download PDF

Info

Publication number
CA2348779A1
CA2348779A1 CA002348779A CA2348779A CA2348779A1 CA 2348779 A1 CA2348779 A1 CA 2348779A1 CA 002348779 A CA002348779 A CA 002348779A CA 2348779 A CA2348779 A CA 2348779A CA 2348779 A1 CA2348779 A1 CA 2348779A1
Authority
CA
Canada
Prior art keywords
domain
rna
allosteric
ligand
ribozyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002348779A
Other languages
English (en)
Inventor
Ronald R. Breaker
Garrett A. Soukup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2348779A1 publication Critical patent/CA2348779A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des polynucléotides à domaines multiples, sensibles aux agents de signalisations, configurés et construits de manière à comprendre au moins trois domaines pouvant se chevaucher partiellement, entièrement ou pas du tout, à savoir un domaine activateur (catalytique ou rapporteur), un domaine de pontage et un domaine récepteur. Dans une forme d'exécution caractéristique, un agent de signalisation tel qu'un ligand chimique interagit avec le domaine récepteur, ce qui modifie ou influence d'une autre manière le domaine de pontage de telle façon que la fonction d'activation, catalytique ou rapporteuse du domaine d'actionnement est stimulée ou inhibée. Dans certaines formes à ribozymes par exemple, des détecteurs moléculaires spécifiques du ligand, composés d'ARN, sont créés par couplage du domaine catalytique et du domaine récepteur préexistants au moyen de nouveaux ponts structurels fonctionnant de la manière suivante : la fixation d'un ligand sur le domaine récepteur provoque une modification de la configuration du pont et cette réorganisation structurelle détermine l'activité du ribozyme contigu. L'invention concerne également des procédés permettant une sélection allostérique d'autres polynucléotides à domaines multiples, ces procédés consistant normalement à répartir et à coupler les domaines de manière à favoriser la liaison ou d'autres signaux réponse et/ou l'activité rapporteuse.
CA002348779A 1998-11-03 1999-10-29 Detecteurs moleculaires polynucleotidiques a domaines multiples Abandoned CA2348779A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10682998P 1998-11-03 1998-11-03
US60/106,829 1998-11-03
US12668399P 1999-03-29 1999-03-29
US60/126,683 1999-03-29
PCT/US1999/025497 WO2000026226A1 (fr) 1998-11-03 1999-10-29 Detecteurs moleculaires polynucleotidiques a domaines multiples

Publications (1)

Publication Number Publication Date
CA2348779A1 true CA2348779A1 (fr) 2000-05-11

Family

ID=26804069

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002348779A Abandoned CA2348779A1 (fr) 1998-11-03 1999-10-29 Detecteurs moleculaires polynucleotidiques a domaines multiples

Country Status (5)

Country Link
EP (1) EP1133513A4 (fr)
JP (1) JP2002528109A (fr)
AU (2) AU772881B2 (fr)
CA (1) CA2348779A1 (fr)
WO (1) WO2000026226A1 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
IL130606A0 (en) * 1999-06-23 2000-06-01 Intelligene Ltd An array of nucleic acid sequence
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2005041859A2 (fr) 2003-04-30 2005-05-12 Sirna Therapeutics, Inc. Conjugues et compositions
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
WO2001096541A2 (fr) * 2000-06-15 2001-12-20 Board Of Regents Ribozymes regules de maniere allosterique
JP2004515219A (ja) * 2000-06-15 2004-05-27 ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム 調節可能な触媒活性な核酸
US6706474B1 (en) 2000-06-27 2004-03-16 Board Of Trustees Of The University Of Illinois Nucleic acid enzyme biosensors for ions
US6949379B2 (en) 2000-10-20 2005-09-27 Canji, Inc. Aptamer-mediated regulation of gene expression
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
JP4358521B2 (ja) 2001-05-18 2009-11-04 サーナ・セラピューティクス・インコーポレイテッド 細胞デリバリーのためのコンジュゲートおよび組成物
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US20030219422A1 (en) * 2001-11-15 2003-11-27 Noxxon Pharma Ag Allosteric ribozymes and uses thereof
US20030219775A1 (en) * 2001-12-14 2003-11-27 Ward David C. Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
US7071311B2 (en) 2002-02-13 2006-07-04 Sirna Therapeutics, Inc. Antibodies having specificity for 2′-C-allyl nucleic acids
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7534560B2 (en) 2002-05-10 2009-05-19 The Board Of Trustees Of The University Of Illinois Simple catalytic DNA biosensors for ions based on color changes
US6890719B2 (en) 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
AU2003261264B2 (en) 2002-07-25 2008-12-11 Archemix Corp. Regulated aptamer therapeutics
EP1546170A4 (fr) * 2002-09-20 2007-08-29 Univ Yale Riboswitchs, procedes d'utilisation et compositions a utiliser avec des riboswitchs
US7612185B2 (en) 2003-03-07 2009-11-03 The Board Of Trustees Of The University Of Illinois Nucleic acid biosensors
US7485419B2 (en) 2004-01-13 2009-02-03 The Board Of Trustees Of The University Of Illinois Biosensors based on directed assembly of particles
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7892734B2 (en) 2005-08-11 2011-02-22 The Board Of Trustees Of The University Of Illinois Aptamer based colorimetric sensor systems
EP1974052A2 (fr) * 2005-12-21 2008-10-01 Yale University Méthodes et compositions associées à la modulation de ribocommutateurs
US7799554B2 (en) 2006-03-16 2010-09-21 The Board Of Trustees Of The University Of Illinois Lateral flow devices
CA2657319C (fr) 2006-07-11 2016-06-21 University Of Medicine And Dentistry Of New Jersey Compositions de mg53 et leur utilisation
US8415461B2 (en) 2007-01-19 2013-04-09 The Board Of Trustees Of The University Of Illinois Amphiphilic substances and functionalized lipid vesicles including the same
US8058415B2 (en) 2007-04-24 2011-11-15 The Board Of Trustees Of The University Of Illinois Aptamer- and nucleic acid enzyme-based systems for simultaneous detection of multiple analytes
US8409800B2 (en) 2007-07-16 2013-04-02 The Board Of Trustees Of The University Of Illinois Nucleic acid based fluorescent sensor for copper detection
US8568690B2 (en) 2007-07-31 2013-10-29 The Board Of Trustees Of The University Of Illinois MRI contrast agents and high-throughput screening by MRI
US8367416B2 (en) 2007-08-10 2013-02-05 The Board Of Trustees Of The University Of Illinois Nucleic acid based fluorescent sensor for mercury detection
US8062893B2 (en) 2008-10-10 2011-11-22 The Board Of Trustees Of The University Of Illinois Fluorescent sensor for mercury
EP3721943A1 (fr) 2009-12-23 2020-10-14 Novartis AG Lipides, compositions de lipides et leurs procédés d'utilisation
EP2600901B1 (fr) 2010-08-06 2019-03-27 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012135805A2 (fr) 2011-03-31 2012-10-04 modeRNA Therapeutics Administration et formulation d'acides nucléiques génétiquement modifiés
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2013161964A1 (fr) * 2012-04-27 2013-10-31 キリンホールディングス株式会社 Molécule d'acide nucléique pouvant détecter avec une grande sensibilité un ligand, ainsi que procédé de criblage de cette molécule d'acide nucléique et procédé d'optimisation de la sensibilité de cette molécule d'acide nucléique
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
AU2014224205C1 (en) 2013-03-08 2019-04-04 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3083579B1 (fr) 2013-12-19 2022-01-26 Novartis AG Lipides et compositions lipidiques destinés à la libération d'agents actifs
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
US10342761B2 (en) 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
JP6731912B2 (ja) 2014-09-05 2020-07-29 ノバルティス アーゲー 活性物質の送達用の脂質および脂質組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU724627B2 (en) * 1996-12-19 2000-09-28 Yale University Bioreactive allosteric polynucleotides

Also Published As

Publication number Publication date
WO2000026226A1 (fr) 2000-05-11
AU2004203816A1 (en) 2004-09-02
JP2002528109A (ja) 2002-09-03
AU1601300A (en) 2000-05-22
AU772881B2 (en) 2004-05-13
EP1133513A4 (fr) 2002-07-03
EP1133513A1 (fr) 2001-09-19

Similar Documents

Publication Publication Date Title
AU772881B2 (en) Multidomain polynucleotide molecular sensors
Tang et al. Rational design of allosteric ribozymes
Soukup et al. Allosteric nucleic acid catalysts
AU724627B2 (en) Bioreactive allosteric polynucleotides
Famulok et al. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy
US6451535B1 (en) Composition containing DNA coding for a ribozyme and an oligonucleotide substrate, and method for measuring transcription rates
Luzi et al. New trends in affinity sensing: aptamers for ligand binding
Jenne et al. A novel ribozyme with ester transferase activity
Soukup et al. Generating new ligand-binding RNAs by affinity maturation and disintegration of allosteric ribozymes.
US20030104520A1 (en) Regulatable, catalytically active nucleic acids
Famulok Allosteric aptamers and aptazymes as probes for screening approaches
Umekage et al. In vitro and in vivo production and purification of circular RNA aptamer
Kopylov et al. Combinatorial chemistry of nucleic acids: SELEX
US20040126882A1 (en) Regulatable, catalytically active nucleic acids
Schmidt et al. RNA double cleavage by a hairpin-derived twin ribozyme
US20060121510A1 (en) Multidomain polynucleotide molecular sensors
JP2005533862A (ja) 調節されたアプタマー治療剤
Koizumi et al. Allosteric ribozymes sensitive to the second messengers cAMP and cGMP
Ellington et al. Combinatorial methods: aptamers and aptazymes
Müller et al. Sensors made of RNA: tailored ribozymes for detection of small organic molecules, metals, nucleic acids and proteins
Silverman Nucleic acid switches and sensors
Zhou et al. Endowing RNase H-inactive antisense with catalytic activity: 2-5A-morphants
US20040219581A1 (en) pH dependent signaling DNA enzymes
Polisky Progress towards Therapeutic Application of SELEX-derived Aptamers
Yang et al. 2 Prospects forthe De Novo

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued